There were 1,683 press releases posted in the last 24 hours and 454,627 in the last 365 days.

Angiogenesis Inhibitors Market is projected to grow at a CAGR of 9.20% during the forecast period to 2029

Angiogenesis Inhibitors Market

Angiogenesis Inhibitors Market is projected to grow at a CAGR of 9.20% during the forecast period to 2029

PUNE, MAHARASHTRA, INDIA, October 13, 2022 / -- The high prevalence of the different types of cancer affecting number of people is expected to help the angiogenesis inhibitors market to experience tremendous growth within the forecast period. Moreover, the market is expected to show a negative growth within the forecast period due to the effects of restrictions caused by sudden outbreak of COVID-19.

Data Bridge Market Research analyses that the angiogenesis inhibitors market will grow at a CAGR of 9.20% during the forecast period of 2022 to 2029. The “VEGF targeted therapy” accounts for the product segment in the angiogenesis inhibitors market within the forecasted period.

Get Sample PDF of the Report –

Some of the major players operating in the angiogenesis inhibitors market are F. Hoffmann-La Roche Ltd, Pfizer Inc., Exelixis, Inc, Novartis AG, Takeda Pharmaceutical Company Limited, Melinta Therapeutics LLC, Cipla Inc., Sun Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Balaji Medical Services Private Limited, Eli Lilly and Company, Bayer AG, Sanofi and Merck & Co., among others.

Global Angiogenesis Inhibitors Market Definition
The formation of new blood vessels is known as angiogenesis. Anti-angiogenics, also referred as angiogenesis inhibitors, are substances that block the process of angiogenesis. These drugs are crucial in the treatment of certain cancers. Angiogenesis inhibitors are different from other cancer-fighting drugs in that they stop the growth of blood vessels that support tumor growth rather than stopping tumor cells from growing.

Angiogenesis Inhibitors Market Dynamics
Growing Cases of Cancer
The increasing burden of cancer such as breast cancer, prostate cancer and lung cancer globally will result in the expansion of the growth rate of the treatment market.

Moreover, the research and development investments generates novel therapies are also the growth determinants which bolster the growth of the market. Also, the availability of treatment options and robust pipeline that leads to potential drugs will further enhance the growth of angiogenesis inhibitors market.

Furthermore, advancement in medical technology and rise in the increasing adverse effects from chemotherapy are the cancer that will expand the angiogenesis inhibitors market. Other factors such as increase in the demand for effective treatment procedures will positively impact the angiogenesis inhibitors market's growth rate.


Moreover, the government initiatives to increase cancer awareness will boost new opportunities for the market's growth rate. Also, the developments in healthcare technology will escalate the growth rate angiogenesis inhibitors market in future.

To get more insights into Market Analysis, browse Research Report Summary @:-

Global Angiogenesis Inhibitors Market Scope
The angiogenesis inhibitors market is segmented on the basis of product, indication, drugs, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.


VEGF Targeted Therapy
FGF Targeted Therapies
Oncogene Targeted Therapy
Matrix Degrading and Remodeling Targeted Therapy
On the basis of product, angiogenesis inhibitors market is segmented into VEGF targeted therapy, FGF targeted therapies, oncogene targeted therapy, matrix degrading and remodeling targeted therapy and others. VEGF targeted therapy segment is expected to grow at the fastest CAGR during the forecast period.


Colorectal Cancer
On the basis of indication, angiogenesis inhibitors market is segmented into glioblastoma, colorectal cancer and others.

Route of Administration

On the basis of route of administration, the angiogenesis inhibitors market is segmented into oral, parenteral and others.


Specialty Clinics
On the basis of end-users, the angiogenesis inhibitors market is segmented into hospitals, specialty clinics and others.

Distribution Channel

Hospital Pharmacy
Retail Pharmacy
On the basis of distribution channel, the angiogenesis inhibitors market is segmented into hospital pharmacy, retail pharmacy and others.

Angiogenesis Inhibitors Market Regional Analysis/Insights
The angiogenesis inhibitors market is analyzed and market size insights and trends are provided by country, product, indication, drugs, route of administration, end-users and distribution channel as referenced above.

The countries covered in the angiogenesis inhibitors market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the angiogenesis inhibitors market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing incidence of cancer in the country, the presence of key market players, and the launch of new commodities influence market growth in this region. Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period due to the factors such as the surging awareness about early diagnosis, growth in healthcare expenditure, high unmet clinical needs of patients as well as the effective treatment in emerging countries such as China and India in the region.

Browse Complete TOC at-

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Top Healthcare Report Links:-

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Sopan Gedam
Data Bridge Market Research
+1 888-387-2818
email us here